profit from every $100 of sales.
$0$100
111
$2.84-0.35% today
-29.9% in 1 year
1-year low $2.561-year high $8.38
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What 111 sold, what it kept, and what it did with the cash.
Sales went from CN¥13.5 billion in 2022 to CN¥12.6 billion in 2025, with -CN¥66.4 million of profit last year.
SalesProfit
111 vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| 111 | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads 111's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 13,517 | 14,948 | 14,401 | 12,556 | |
| 840 | 849 | 829 | 723 | |
| -371 | -350 | 2 | -2 | |
| -322 | -311 | 25 | 25 | |
| -417 | -393 | -65 | -66 | |
| -50.00 | -46.60 | -7.60 | – | |
| 6.2% | 5.7% | 5.8% | 5.8% | |
| -2.7% | -2.3% | 0.0% | -0.0% | |
| -3.1% | -2.6% | -0.4% | -0.5% |
Balance sheet
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,474 | 3,089 | 2,788 | 2,200 |
| Cash | 674 | 604 | 462 | 511 |
| Total debt | 344 | 443 | 257 | 237 |
| Total liabilities | 2,826 | 2,813 | 2,407 | 1,986 |
| -415 | -583 | -643 | -702 | |
| 8 | 8 | 9 | – | |
| – | – | – | – | |
| 100.5% | 67.3% | 10.1% | 9.5% |
Cash flow
| In millions of CNY | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -447 | 263 | 119 | |
| 32 | 10 | 15 | 4 | |
| -55 | -457 | 248 | 115 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 162 | 227 | 20 | 10 |
Valuation
- –
- –
- –
- -0.5×
- 0.0×
- 1.5×
- –
- 68.9%
- -39.9%
- 0.0%
Profitability
- 5.8%
- -0.0%
- -0.5%
- 0.0%
- -1.5%
- 136.3%
- 8.3%
- -2.5%
- -2.7%
- –
Growth
- −2.4%
- –
- −53.7%
- –
- +1.2%
Financial health
- -95.9×
- -0.31
- 9.9%
- -0.2×
- 1.09
- 0.58
- 5.69
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 946
Bottom 21%of 872
Bottom 12%of 868
Top 1%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 9, 2026 | -0.20 | – | – |
| Dec 17, 2025 | -0.20 | – | – |
| Sep 17, 2025 | -0.40 | – | – |
| Jun 19, 2025 | -0.20 | – | – |
| Mar 20, 2025 | -0.04 | – | – |
| Nov 27, 2024 | -0.20 | – | – |
| Aug 29, 2024 | -0.20 | – | – |
| May 23, 2024 | -0.20 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
12No pass
Philip Fisher
37No pass
Peter Lynch
9No pass
Joel Greenblatt
2No pass
Charlie Munger
33No pass
Terry Smith
35No pass
Questions about 111
Is 111 a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the 111 AI analysis
What does 111 do?
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. It is in Medical - Pharmaceuticals.
Does 111 pay a dividend?
No. 111 does not pay a dividend at the moment.
Is 111 stock halal?
No. 111 does not pass our halal screen: its debt is 142% of its market value, at or above the 33% limit. How we check
How has 111 stock done over the past year?
Down 29.9% over the past twelve months, to $2.84. It traded between $2.56 and $8.38 and is 66.1% below its high.
Who are 111's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with 111's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.